Literature DB >> 11041277

N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test.

K Aoyama1, K Matsubara, K Okada, S Fukushima, K Shimizu, S Yamaguchi, T Uezono, M Satomi, N Hayase, S Ohta, H Shiono, S Kobayashi.   

Abstract

The discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) leads to the hypothesis that Parkinson's disease (PD) is may be initiated or precipitated by endogenous toxins by the mechanism similar to that of MPTP in genetically-predisposed individuals. The higher cerebrospinal fluid levels of N-methylated azaheterocyclic amines, such as beta-carboline and tetrahydroisoquinoline, have been found in parkinsonian patients compared with age-matched controls. To estimate the N-methylation ability for azaheterocyclic amines in parkinsonian patient, nicotinamide was dosed with 100 mg to 26 parkinsonians and 20 controls consisted of 16 other neurogenic disease patients and 4 healthy volunteers. The urine was collected for 4 h, and then analyzed urinary its metabolites by an improved HPLC method. Nicotinamide has a pyridine ring in its structure and may be metabolized through the pathways similar to those for the endogenous neurotoxins. The urinary excretions of nicotinamide metabolites were significantly affected by aging. The excretion of N1-methylnicotinamide decreased along with aging both in PD patients and controls. In younger (65 years old or younger) PD patients, the excretion amount of N1-methylnicotinamide was significantly higher than that in younger controls. The decline rate of N1-methylnicotinamide excretion in parkinsonians was significantly greater than that in controls; the rate is more than 2-fold higher in parkinsonian patients. The age-associated decrease in 1-methyl-2-pyridone-5-carboxyamide excretion was observed only in parkinsonian patients, but not in controls. The total excreted amount of N-methylated metabolites (N1-methylnicotinamide plus 1-methyl-2-pyridone-5-carboxyamide) was also observed the age-related decline in both groups. The urinary excretions of nicotinamide and nicotinamide-N-oxide were not influenced by aging. These results would indicate that the excess N-methylation ability for azaheterocyclic amines before the onset had been implicated in PD. On the other hand, the present results suggested that the contribution of aberrant cytochrome P450 or aldehyde oxidase activity acting on the pyridine ring, that could act as detoxification routes of endogenous neurotoxins, would be small in the etiology of PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11041277     DOI: 10.1007/s007020070047

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  11 in total

1.  Effects of N1-methylnicotinamide on oxidative and glycooxidative stress markers in rats with streptozotocin-induced diabetes mellitus.

Authors:  Zuzana Országhová; Ol'ga Uličná; Anna Liptáková; Ingrid Zitňanová; Jana Muchová; Cezary Watala; Zdeňka Duračková
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

2.  Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.

Authors:  G Muthian; V Mackey; J King; C G Charlton
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

3.  The age-related increase in N-methyl-2-pyridone-5-carboxamide (NAD catabolite) in human plasma.

Authors:  Ewa M Slominska; Przemyslaw Rutkowski; Ryszard T Smolenski; Andrzej Szutowicz; Boleslaw Rutkowski; Julian Swierczynski
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

4.  Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure.

Authors:  Ewa M Slominska; Katarzyna Kowalik; Ryszard T Smolenski; Marek Szolkiewicz; Przemyslaw Rutkowski; Boleslaw Rutkowski; Julian Swierczynski
Journal:  Pediatr Nephrol       Date:  2006-04-08       Impact factor: 3.714

5.  Inhibitory effects of lysophosphatidylcholine on the dopaminergic system.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Kennie R Shepherd; Nazarius S Lamango; Karam F A Soliman; Clivel G Charlton
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

6.  Excessive S-adenosyl-L-methionine-dependent methylation increases levels of methanol, formaldehyde and formic acid in rat brain striatal homogenates: possible role in S-adenosyl-L-methionine-induced Parkinson's disease-like disorders.

Authors:  Eun-Sook Lee; Hongtao Chen; Chadwick Hardman; Anthony Simm; Clivel Charlton
Journal:  Life Sci       Date:  2008-10-05       Impact factor: 5.037

7.  1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.

Authors:  S Chlopicki; J Swies; A Mogielnicki; W Buczko; M Bartus; M Lomnicka; J Adamus; J Gebicki
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

8.  Effects of 1-Methylnicotinamide (MNA) on Exercise Capacity and Endothelial Response in Diabetic Mice.

Authors:  Kamil Przyborowski; Marta Wojewoda; Barbara Sitek; Agnieszka Zakrzewska; Agnieszka Kij; Krystyna Wandzel; Jerzy Andrzej Zoladz; Stefan Chlopicki
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

9.  Novel Inhibitors of Nicotinamide-N-Methyltransferase for the Treatment of Metabolic Disorders.

Authors:  Aimo Kannt; Sridharan Rajagopal; Mahanandeesha S Hallur; Indu Swamy; Rajendra Kristam; Saravanakumar Dhakshinamoorthy; Joerg Czech; Gernot Zech; Herman Schreuder; Sven Ruf
Journal:  Molecules       Date:  2021-02-13       Impact factor: 4.411

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.